Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VHL | P40337 | 1/20 | 0.46 |
| ▸ | ELOC | Q15369 | 1/20 | 0.46 |
| ▸ | ELOB | Q15370 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | AOC2 | O75106 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | NSD2 | O96028 | 1/20 | 0.33 |
| ▸ | GRK2 | P25098 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4307851 | 0.81 | POLB (0.39) | VHLELOCELOBMAPTAOC2 | |
| SCHEMBL17828141 | 0.81 | POLB (0.42) | VHLELOCELOBMAPTAOC2 | |
| SCHEMBL27532059 | 0.80 | POLB (0.51) | MAPTAOC2POLBALDH1A1KDM4E | |
| SCHEMBL16720436 | 0.75 | POLB (0.42) | VHLELOCELOBMAPTAOC2 | |
| SCHEMBL19996086 | 0.71 | HRH4 (0.50) | MAPTALDH1A1MAPK1LMNAL3MBTL1 | |
| SCHEMBL24375524 | 0.71 | IRAK4 (0.38) | CSNK1DCSNK1EIRAK4NOTUM | |
| SCHEMBL24375516 | 0.71 | RAB9A (0.44) | MAPTNPC1RAB9AALDH1A1KDM4E | |
| SCHEMBL28047779 | 0.71 | MAPT (0.50) | MAPTAOC2NPC1RAB9APOLB | |
| SCHEMBL5861792 | 0.71 | UHRF1 (0.46) | MAPTNPC1RAB9APOLBALDH1A1 | |
| SCHEMBL2380248 | 0.71 | MAPT (0.41) | VHLELOCELOBMAPTAOC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-9586951-B2 | Morpholine derivative or salt thereof | FUJIFILM CORPORATION (JP) | 2017-03-07 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | FUJIFILM CORPORATION (JP) | 2016-06-16 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | CIBA CORP. | 2009-02-19 | — | — | US | disclosed |
| EP-1981635-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | Ciba Holding Inc. (CH) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007090461-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA HOLDING INC. (CH) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007090461-A1 | USE OF METAL COMPLEX COMPOUNDS AS OXIDATION CATALYSTS | CIBA HOLDING INC. (CH) | 2007-08-16 | — | — | WO | disclosed |
| EP-0784612-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-07-23 | — | — | EP | disclosed |
| WO-1996010559-A1 | UREA DERIVATIVES AND THEIR USE AS ACAT-INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168139-A1 | NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF | PRMT7, RBBP7, RER1 | VHL 4430/4885ELOC 3241/4885ELOB 3729/4885 |
| US-20090044345-A1 | Use of Metal Complex Compounds as Oxidation Catalysts | MT-CO2, MT-CO1, SOD1 | VHL 3731/4885ELOC 2332/4885ELOB 2940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.